Current issues of molecular diagnostics of bladder cancer

Dana G. Nurman; Akzhol K. Karim; Shokhrukh K. Akhnazarov; Sultan T. Mukashev; Olzhas M. Demissenov

doi:10.53730/ijhs.v5n3.1477

Authors

Dana G. Nurman
d.nurman6298@uohk.com.cn
Astana Medical University, Nur-Sultan, Republic of Kazakhstan
Akzhol K. Karim Astana Medical University, Nur-Sultan, Republic of Kazakhstan
Shokhrukh K. Akhnazarov Astana Medical University, Nur-Sultan, Republic of Kazakhstan
Sultan T. Mukashev Astana Medical University, Nur-Sultan, Republic of Kazakhstan
Olzhas M. Demissenov Astana Medical University, Nur-Sultan, Republic of Kazakhstan

Keywords:

chemotherapy, antiangiogenic therapy, malignant tumors, tumor marker, tumor

Abstract

Nowadays, it is generally accepted that cancer is a genetic disease. Tumour cells appear due to the accumulation of mutations in critical proto-oncogenes and tumour suppressor genes. Urothelial bladder cancer is a frequent oncological pathology, and therefore it is a significant social problem. The practical relevance of the study is due to the fact that the findings can significantly improve the efficiency of bladder cancer diagnosis. The purpose of the study was to consider all modern methods for diagnosing bladder cancer in one paper. As a research method, the analysis of scientific data obtained from the experimental study of bladder cancer was carried out. According to the data of the investigated sources, a fairly large number of scientists believe that bladder cancer (BC) is one of the most common tumours affecting the urinary tract. It is believed that important prognostic factors include the presence of vascular invasion and tumour complexes in the vessels, which increases the risk of the secondary neoplasm growth even at the pT1 stage. However, when assessing vascular invasion, pathologists often mistake the cracks formed around the tumour complexes for vessels. In this case, the study suggests conducting an immunohistochemical analysis for clear visualisation of blood vessels.

Downloads

Download data is not yet available.

References

Abdel-Rahman, O. (2019). Bladder cancer mortality after a diagnosis of nonmuscle-invasive bladder carcinoma. Future Oncology, 15(19), 2267-2275.

Alifrangis, C., McGovern, U., Freeman, A., Powles, T., & Linch, M. (2019). Molecular and histopathology directed therapy for advanced bladder cancer. Nature Reviews Urology, 16(8), 465-483.

Attallah, A. M., Sakr, H. A., Ismail, H., Ismail, M. F., Ibrahim, A. S., El-Sharabasy, M. M., & El-Dosoky, I. (2006). Rapid diagnosis and follow up of bladder cancer patients using urinary high molecular weight cytokeratins. World journal of urology, 24(3), 345-352.

Blagosklonny, M. V. (2004). Antiangiogenic therapy and tumor progression. Cancer cell, 5(1), 13-17. https://doi.org/10.1016/S1535-6108(03)00336-2

Chan, E., Garg, K., & Stohr, B. A. (2020). Integrated immunohistochemical and molecular analysis improves diagnosis of high-grade carcinoma in the urinary bladder of patients with prior radiation therapy for prostate cancer. Modern Pathology, 33(9), 1802-1810.

Chapelier, A. R., Missana, M. C., Couturaud, B., Fadel, E., Fabre, D., Mussot, S., ... & Dartevelle, P. G. (2004). Sternal resection and reconstruction for primary malignant tumors. The Annals of thoracic surgery, 77(3), 1001-1007. https://doi.org/10.1016/j.athoracsur.2003.08.053

Dharmayuda, T. G., Suega, K., Bakta, I. M., & Sumohadi, I. M. D. (2021). Ki67 expression and prognostic aspects of colorectal cancer. International Journal of Health Sciences, 5(2), 79-88. https://doi.org/10.29332/ijhs.v5n2.1215

Elliott, J., Rotterud, R., Maddox-Smith, A., Bagshaw, K., Cirefice, L. B. F., Knight, A., ... & Makaroff, L. E. (2019). The bladder cancer patient survey: Global perspectives on awareness and treatment of bladder cancer. Journal of Cancer Policy, 22, 100207.

Garden, A. S., El-Naggar, A. K., Morrison, W. H., Callender, D. L., Ang, K. K., & Peters, L. J. (1997). Postoperative radiotherapy for malignant tumors of the parotid gland. International Journal of Radiation Oncology* Biology* Physics, 37(1), 79-85. https://doi.org/10.1016/S0360-3016(96)00464-6

Glimelius, B., Ekström, K., Hoffman, K., Graf, W., Sjödén, P. O., Haglund, U., ... & Heuman, R. (1997). Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Annals of Oncology, 8(2), 163-168. https://doi.org/10.1023/A:1008243606668

Glimelius, B., Hoffman, K., Sjödén, P. O., Jacobsson, G., Sellström, H., Enander, L. K., ... & Svensson, C. (1996). Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Annals of oncology, 7(6), 593-600. https://doi.org/10.1093/oxfordjournals.annonc.a010676

Glybchenko, P. V., Shakhpazian, N. K., Ponukalin, A. N., & Zakharova, N. B. (2011). Molecular markers for the diagnosis of non-muscle-invasive bladder cancer. Klinicheskaia laboratornaia diagnostika, (5), 16-20.

Grunnet, M., & Sorensen, J. B. (2012). Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. Lung cancer, 76(2), 138-143. https://doi.org/10.1016/j.lungcan.2011.11.012

Jayson, G. C., Kerbel, R., Ellis, L. M., & Harris, A. L. (2016). Antiangiogenic therapy in oncology: current status and future directions. The Lancet, 388(10043), 518-529. https://doi.org/10.1016/S0140-6736(15)01088-0

Jordan, B., & Meeks, J. J. (2019). T1 bladder cancer: current considerations for diagnosis and management. Nature Reviews Urology, 16(1), 23-34.

Kamat, A. M., Hegarty, P. K., Gee, J. R., Clark, P. E., Svatek, R. S., Hegarty, N., ... & Karakiewicz, P. I. (2013). ICUD-EAU International Consultation on Bladder Cancer 2012: Screening, diagnosis, and molecular markers. European urology, 63(1), 4-15.

Kurtieva, S., Nazarova, J., & Mullajonov, H. (2021). Features of endocrine and immune status in adolescents with vegetative dystonia syndrome. International Journal of Health Sciences, 5(2), 118-127. https://doi.org/10.29332/ijhs.v5n2.1332

Lähdevirta, J., Maury, C. P. J., Teppo, A. M., & Repo, H. (1988). Elevated levels of circulating cachectin/tumor necrosis factor in patients with acquired immunodeficiency syndrome. The American journal of medicine, 85(3), 289-291. https://doi.org/10.1016/0002-9343(88)90576-1

Leon, M. E., Qin, D., & Zynger, D. L. (2014). Molecular Diagnosis of Bladder and Kidney Cancer. Molecular Pathology and Diagnostics of Cancer, 329-340.

Michal, M., Hes, O., & Havlicek, F. (2000). Benign renal angiomyoadenomatous tumor: a previously unreported renal tumor. Annals of diagnostic pathology, 4(5), 311-315. https://doi.org/10.1053/adpa.2000.17890

Musquera, M., Mengual, L., & Ribal, M. J. (2013). Non-invasive diagnosis bladder cancer: new molecular markers and future perspectives. Archivos espanoles de urologia, 66(5), 487-494.

Parsons, S. R., Hill, G. T., Warren, K. S., & Burden, H. P. (2020). Bladder cancer in the elderly: A retrospective analysis of bladder cancer in individuals older than 85 years. Journal of Clinical Urology, 13(2), 110-115.

Schmitz-Dräger, B. J., Droller, M., Lokeshwar, V. B., Lotan, Y., M''Liss, A. H., Van Rhijn, B. W., ... & Shariat, S. F. (2015). Molecular markers for bladder cancer screening, early diagnosis, and surveillance: the WHO/ICUD consensus. Urologia internationalis, 94(1), 1-24.

Shapiro, A., Gofrit, O. N., Pizov, G., Cohen, J. K., & Maier, J. (2011). Raman molecular imaging: a novel spectroscopic technique for diagnosis of bladder cancer in urine specimens. European urology, 59(1), 106-112.

Shiryaev, A.A., Govorov, A.V., Vasiliev, A.O., Okishev, A.V., Kim, Yu.A., Fedina, M.S., ... & Pushkar, D. Y. (2020). Molecular biomarkers in the diagnosis of bladder cancer. Oncourology, (1), 100-105.

Sun, X., Hoadley, K. A., Kim, W. Y., Furberg, H., Olshan, A. F., & Troester, M. A. (2017). Age at diagnosis, obesity, smoking, and molecular subtypes in muscle-invasive bladder cancer. Cancer Causes & Control, 28(6), 539-544.

Unoki, M., Kelly, J. D., Neal, D. E., Ponder, B. A. J., Nakamura, Y., & Hamamoto, R. (2009). UHRF1 is a novel molecular marker for diagnosis and the prognosis of bladder cancer. British journal of cancer, 101(1), 98-105.

Widana, I.K., Sumetri, N.W., Sutapa, I.K., Suryasa, W. (2021). Anthropometric measures for better cardiovascular and musculoskeletal health. Computer Applications in Engineering Education, 29(3), 550–561. https://doi.org/10.1002/cae.22202

Wu, L. L., & Wu, J. T. (2002). Hyperhomocysteinemia is a risk factor for cancer and a new potential tumor marker. Clinica chimica acta, 322(1-2), 21-28. https://doi.org/10.1016/S0009-8981(02)00174-2

Yang, X. F., Pang, J. Z., Liu, J. H., Zhao, Y., Jia, X. Y., Li, J., ... & Zhang, X. L. (2014, November). Homing peptide guiding optical molecular imaging for the diagnosis of bladder cancer. In Optics in Health Care and Biomedical Optics VI (Vol. 9268, p. 92681P). International Society for Optics and Photonics.

Yoshida, T., Kates, M., Fujita, K., Bivalacqua, T. J., & McConkey, D. J. (2019). Predictive biomarkers for drug response in bladder cancer. International Journal of Urology, 26(11), 1044-1053.

Zhang, P., Zhang, Y., Liu, W., Cui, D., Zhao, X., Song, J., ... & Fan, J. (2019). A molecular beacon based surface-enhanced Raman scattering nanotag for noninvasive diagnosis of bladder cancer. Journal of biomedical nanotechnology, 15(7), 1589-1597.

Zhao, J., He, D., He, H., Li, L., Zhang, L. L., & Wang, X. Y. (2007). Primary application study in early diagnosis of bladder cancer by survivin molecular beacons. Urology, 70(1), 60-64.